Summary of primary NK-cell lymphoma/leukemia cases
| Patient no. . | Sex . | Age . | Diagnosis . | Origin . | EBER-ISH . | sCD3 . | CD2 . | CD5 . | CD20 . | CD56 . | TCRre . | Cytotoxic molecules . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NKpt1 | M | 84 | Extranodal NK/T-cell lymphoma, nasal type | Orbit | + | − | + | − | − | + | ND | TIA-1+, granzyme B+ |
| NKpt2 | M | 57 | Extranodal NK/T-cell lymphoma, nasal type | Skin | − | + | + | − | − | + | − | TIA-1+, granzyme B+ |
| NKpt3 | M | 58 | Aggressive NK-cell leukemia | Peripheral blood | + | − | + | − | − | + | ND | TIA-1−, granzyme B− |
| NKpt4 | M | 68 | Extranodal NK/T-cell lymphoma, nasal type | Nasal cavity | + | + | + | − | − | + | ND | TIA-1+, granzyme B+ |
| NKpt5 | M | 44 | Extranodal NK/T-cell lymphoma, nasal type | Nasal cavity | + | − | + | − | − | + | − | TIA-1+, granzyme B+ |
| NKpt6 | M | 53 | Extranodal NK/T-cell lymphoma, nasal type | Nasal cavity | + | − | + | − | − | + | − | TIA-1+, granzyme B− |
| NKpt7 | F | 68 | Extranodal NK/T-cell lymphoma, nasal type | Nasal cavity | ND | − | + | − | − | + | ND | TIA-1+, granzyme B+ |
| NKpt8 | M | 60 | Aggressive NK-cell leukemia | Bone marrow | + | − | + | − | − | + | − | ND |
| NKpt9 | M | 75 | Extranodal NK/T-cell lymphoma, nasal type | Nasal cavity | + | − | + | − | − | + | ND | TIA-1+, granzyme B− |
| NKpt10 | M | 56 | Aggressive NK-cell leukemia | Bone marrow | + | − | + | − | − | + | ND | TIA-1+, granzyme B+ |
| Patient no. . | Sex . | Age . | Diagnosis . | Origin . | EBER-ISH . | sCD3 . | CD2 . | CD5 . | CD20 . | CD56 . | TCRre . | Cytotoxic molecules . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NKpt1 | M | 84 | Extranodal NK/T-cell lymphoma, nasal type | Orbit | + | − | + | − | − | + | ND | TIA-1+, granzyme B+ |
| NKpt2 | M | 57 | Extranodal NK/T-cell lymphoma, nasal type | Skin | − | + | + | − | − | + | − | TIA-1+, granzyme B+ |
| NKpt3 | M | 58 | Aggressive NK-cell leukemia | Peripheral blood | + | − | + | − | − | + | ND | TIA-1−, granzyme B− |
| NKpt4 | M | 68 | Extranodal NK/T-cell lymphoma, nasal type | Nasal cavity | + | + | + | − | − | + | ND | TIA-1+, granzyme B+ |
| NKpt5 | M | 44 | Extranodal NK/T-cell lymphoma, nasal type | Nasal cavity | + | − | + | − | − | + | − | TIA-1+, granzyme B+ |
| NKpt6 | M | 53 | Extranodal NK/T-cell lymphoma, nasal type | Nasal cavity | + | − | + | − | − | + | − | TIA-1+, granzyme B− |
| NKpt7 | F | 68 | Extranodal NK/T-cell lymphoma, nasal type | Nasal cavity | ND | − | + | − | − | + | ND | TIA-1+, granzyme B+ |
| NKpt8 | M | 60 | Aggressive NK-cell leukemia | Bone marrow | + | − | + | − | − | + | − | ND |
| NKpt9 | M | 75 | Extranodal NK/T-cell lymphoma, nasal type | Nasal cavity | + | − | + | − | − | + | ND | TIA-1+, granzyme B− |
| NKpt10 | M | 56 | Aggressive NK-cell leukemia | Bone marrow | + | − | + | − | − | + | ND | TIA-1+, granzyme B+ |
EBER-ISH indicates EBER in situ hybridization; ND, not determined; NK, natural killer; TCRre, T-cell receptor rearrangement; +, positive stain; and −, negative stain.